Bank Of New York Mellon Corp Genprex, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.76 - $1.78 $13,352 - $31,272	17,569 New	17,569 $16 Million
Q4 2022 Feb 14, 2023	BUY	$1.0 - $58.8 $17,569 - $1.03 Million	17,569 New	17,569 $25,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $1,523 - $2,748	-1,190 Reduced 6.34%	17,569 $24,000
Q3 2021 Nov 12, 2021	SELL	$2.59 - $3.36 $5,413 - $7,022	-2,090 Reduced 10.02%	18,759 $50,000
Q2 2021 Aug 11, 2021	SELL	$3.11 - $4.87 $178,821 - $280,020	-57,499 Reduced 73.39%	20,849 $69,000
Q1 2021 May 13, 2021	SELL	$3.66 - $7.67 $44,882 - $94,057	-12,263 Reduced 13.53%	78,348 $337,000
Q4 2020 Feb 09, 2021	BUY	$3.03 - $5.51 $59,445 - $108,100	19,619 Added 27.64%	90,611 $376,000
Q3 2020 Nov 12, 2020	SELL	$2.9 - $4.29 $51,312 - $75,907	-17,694 Reduced 19.95%	70,992 $238,000
Q2 2020 Aug 12, 2020	BUY	$1.99 - $3.64 $127,117 - $232,515	63,878 Added 257.49%	88,686 $278,000
Q1 2020 May 06, 2020	BUY	$0.28 - $6.23 $6,946 - $154,553	24,808 New	24,808 $60,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.